New Clinical and Scientific Data on TWYMEEG
LYON, France--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that new clinical and scientific data on TWYMEEG ® will be presented at the 68 th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan.
A total of 15 presentations 1, including results from 7 clinical trials, 3 post-hoc analyses 2 and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG ® 's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include:
TWINKLE (TW YMEEG ® in d i abetic patients with re n al impairment: A post-mar k eting l ong-t e rm study) study (Phase 4 study): confirmation of TWYMEEG ® efficacy and safety in diabetic patients with renal impairment
FAMILIAR Study: confirmation of TWYMEEG ® efficacy and safety in combination with DPP-4 inhibitors
PARADIME Clamp: confirmation of TWYMEEG ® dual mechanism of action in diabetic patients – clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part)
PARADIME TIR: confirmation of TWYMEEG ® effects on glucose variability
PET/MRI Study: confirmation of TWYMEEG ® effect on glucose excretion in the gut
Thomas Kuhn, Chief Executive Officer of Poxel, stated: 'We are proud to see the scientific community's continued interest and the commitment of our partner Sumitomo Pharma to document and promote TWYMEEG ® 's attributes and value. These presentations further support the product's clinical and commercial trajectory in Japan. They also highlight its value proposition for Japan and other territories and its unique profile across diverse patient subgroups.'
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
Appendix
A post-marketing clinical trial to evaluate the safety, tolerability, and efficacy of Imeglimin in Japanese type 2 diabetes patients with renal impairment (Twinkle Study results;Phase 4)
Imeglimin was shown to be safe and effective in patients with T2D associated with renal dysfunction with eGFR less than 45 mL/min/1.73 m2
Dr. Babazono
Ishikawa Memorial Association
Clinical
Efficacy and safety of Imeglimin as an add-on treatment in type 2 diabetes patients treated with DPP-4 inhibitors: interim analysis of the FAMILIAR study
Combination therapy of Imeglimin and DPP-4 inhibitors significantly reduced HbA1c at 24 weeks in type 2 diabetes patients with inadequate glycemic control with DPP-4 inhibitor therapy, confirming that Imeglimin may be a new treatment option when combined with a DPP-4 inhibitor regardless of age.
Dr. Kaku
Kawasaki Medical School
Clinical
Comparison of the effects of Imeglimin and metformin on insulin and incretin secretion
Imeglimin enhanced insulin secretion as well as increased not only GLP-1 but also GIP secretion, unlike metformin
Dr. Omori
Kansai Electric Power Hospital
Clinical
Effect of Imeglimin use on Time in Range in type 2 diabetes: A multicenter randomized controlled trial (Paradime-TIR)
Imeglimin alone and in combination with DPPIV inhibitors increased Time in Range by more than 10% without increasing Time Below Range, confirming the efficacy of the product in reducing glycemic variability
Dr. Ueda
Kobe Univ.
Clinical
The effects of Imeglimin and metformin on insulin secretion and sensitivity (Paradime-Clamp; OGTT part)
No differences were observed between Imeglimin and Metformin on glucose lowering effects, and on insulin secretion and insulin sensitivity effects
Dr. Yamada
Kobe Univ.
Clinical
The effects of Imeglimin and metformin on insulin secretion and sensitivity (Paradime-Clamp; Clamp part)
No differences were observed between Imeglimin and Metformin on insulin secretion, insulin sensitivity and their ability to switch energy sources
Dr. Katsura
Kobe Univ.
Clinical
Effects on glucose excretion to gut by using FDG/PET MRI study
Imeglimin improved glucose excretion into the intestinal lumen
Dr. Fukumitsu
Kobe Univ.
Clinical
Post-hoc analysis (Atypical cluster analysis of Imeglimin + Metformin)
The highest A1c reduction of the combination Imeglimin + metformin was observed in obese patients or those with a high baseline HbA1c
Kitayama
SMP
Clinical
Post-hoc analysis: Insulin combination therapy
Combination therapy with Imeglimin and insulin exerted glucose lowering effects independent of obesity type
Hagi, PhD
SMP
Clinical
Post-hoc analysis: Monotherapy
Imeglimin monotherapy exerted glucose lowering effects independent of obesity type
Maruyama
SMP
Clinical
Vascular protection effects of Imeglimin, a mitochondrial function-improving drug
Imeglimin showed protective effect against vascular lesions like SGLT2 inhibitors and GLP-1 receptor agonists
Dr. Iwazawa
Juntendo Univ. Shizuoka Hospital
Non-clinical
Effect of Imeglimin on diabetic neuropathy in type 1 diabetic rat models
Imeglimin may be effective against diabetic neuropathy as shown in this study in STZ-induced diabetic rats,
Dr. Nihei
Aichi Gakuin Univ.
Non-clinical
Combined effects of anaerobic exercise and Imeglimin on skeletal muscles
The combination of Resistance Training and Imeglimin may be an effective treatment by improving mitochondrial function, glucose metabolism and glucose uptake
Dr. Ishiguro
Niigata Univ.
Non-clinical
Effect of Imeglimin on periodontitis associated with type 1 diabetes
Imeglimin may be useful in preventing the worsening of periodontal disease due to type 1 diabetes.
Dr. Kondo
Aichi Gakuin Univ.
Non-clinical
Imeglimin effect on intestinal gene expression
Imeglimin induced similar gene expression as metformin in the whole intestinal tissue, but single-cell analysis revealed different effects on specific cell types, including intestinal cell clusters and macrophage clusters
Dr. Hozumi
Kobe Univ.
Non-clinical
Expand
_________________________________
1
Detailed program included in Appendix
2
Refers to a statistical analysis specified after a study has been concluded and the data collected
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
a day ago
- New York Post
I spent $200 on the viral ‘Japanese head spa' treatment for hair health — but does it actually work?
Social media is a powerful thing. Especially when you're someone who is inclined to buy something, go somewhere, try something, taste something, wear something, JUST because people online said it's good. Hi, it's me. I'm that person. And for months and months I've been ignoring the videos of people trying out those viral Japanese head spa treatments spammed in my feed on TikTok and Instagram. But then I caved. Toyko Headspa — the Japanese treatment that has content creators frothing I noticed a newish salon was offering the viral treatment that so many people have been raving about online, so of course I had to give it a try. Tokyo Headspa offered at Salon Lane in Sydney, Australia boasts an impressive menu for anyone who just wants to bliss out. Each treatment offers different solutions to boost hair and scalp health, reduce stress and 'leave you feeling like you're floating in a dream…' They're not my words, that's what it promises on the website. But think… the super relaxing head massage you get before your haircut at your local hairdresser, but add another WHOLE HOUR to it. It's that — no matter what treatment you get. I schlepped my tired self and neglected mane to the Bondi Junction salon and opted for the Sakuya Hime treatment. The whole treatment goes for one hour and 40 minutes and is said to encourage hair regrowth — and after two kids and a decent amount of postpartum hair loss, I figured I'd lean in to some benefits as well as much-needed relaxation. Japanese head spa treatments have gone viral for supposedly helping hair and scalp health. X/@ I'll forewarn you… the treatment is $194. I know… Once you settle in to your quiet room, the treatment begins with your therapist selecting which scalp serum and shampoo is best for you. Mine chose something moisturizing and off we went. The experience begins with a relaxing head massage using the selected serum, and it's followed up with a shampoo and detoxifying massage to help cleanse and invigorate the scalp. Prepare for the Japanese Waterfall! Another treatment is applied, followed by some hair and scalp brushing before you're then prepared for the warm and nourishing head bath. This is where the viral Japanese waterfall is applied. If you get the targeted content on social media too, you'll know exactly what I'm talking about! When the waterfall was applied, I thought I had gone to heaven. The warm water gently rinses your hair while encouraging a calm relaxation. It worked. I think I fell asleep. The treatment involves a relaxing 'Japanese waterfall' over the client's head. X/@ The treatment ends with another head, shoulder and neck massage and then your hair is dried off to prepare you to continue on with your day with complete zen. I was warned multiple times that the treatment does NOT include any styling, so I got a sense that this is something they really needed their clients to understand. And I did… until I caught a glimpse of my extremely curly and frizzy hair in a mirror while walking back to the lift post treatment. It wasn't pretty. So does this viral beauty treatment live up to the hype? Now, here's where I get really honest… If you're thinking '$194 for a glorified hair wash, YOU'RE CRAZY!' I hear you loud and clear! This is an experience that is completely indulgent, and if you have a mortgage like me, the price tag stings. But there's no doubt this is a treatment that any tired mum would enjoy. It would make a perfect gift for someone who needs some 'me time' and there are other treatments you can choose that are a little more justifiable.
Business Wire
a day ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
a day ago
NASA spacecraft around the moon photographs the crash site of a Japanese company's lunar lander
CAPE CANAVERAL, Fla. -- A NASA spacecraft around the moon has photographed the crash site of a Japanese company's lunar lander. NASA released the pictures Friday, two weeks after ispace's lander slammed into the moon. The images show a dark smudge where the lander, named Resilience, and its mini rover crashed into Mare Frigoris or Sea of Cold, a volcanic region in the moon's far north. A faint halo around the area was formed by the lunar dirt kicked up by the impact. NASA's Lunar Reconnaissance Orbiter captured the scene last week. The crash was the second failure in two years for Tokyo-based ispace. Company officials plan to hold a news conference next week to explain what doomed the latest mission, launched from Cape Canaveral in January. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
